Jing Rong Cui
Fondateur chez Blossomhill Therapeutics, Inc.
Postes actifs de Jing Rong Cui
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
| Directeur Général | - | - | |
| Fondateur | - | - | |
| President | - | - |
Historique de carrière de Jing Rong Cui
Anciens postes connus de Jing Rong Cui
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TURG POIN | Directeur/Membre du Conseil | 01/10/2013 | 01/09/2018 |
| Président | 01/09/2018 | - | |
| Directeur Technique/Scientifique/R&D | 01/10/2013 | 31/01/2020 | |
| Fondateur | 01/10/2013 | 15/06/2020 | |
| President | 01/04/2018 | 01/01/2019 |
Formation de Jing Rong Cui
| The Ohio State University | Doctorate Degree |
| University of Science & Technology of China | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Chine | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 2 |
| President | 2 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Jing Rong Cui
- Expérience
